Madrigal Pharmaceuticals reported second-quarter 2026 financial results with net revenues of $364.3 million, a 71% increase year-over-year, driven by strong demand for Rezdiffra in the U.S. The company surpassed 50,000 active patients on its MASH treatment and strengthened its intellectual property portfolio with three new patents extending protection into 2042-2045. Operating expenses rose to $420.6 million due to commercial expansion and $25.0 million in one-time business development costs, resulting in a net loss of $57.9 million or $1.99 per share. The company ended the quarter with $838.9 million in cash and marketable securities. Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).

Madrigal Pharmaceuticals, Inc. announced several governance and compensation updates following its June 17, 2026, annual meeting. Stockholders approved the 2026 Stock Plan and the 2026 Employee Stock Purchase Plan. The Board also approved a new Nonqualified Deferred Compensation Plan effective August 1, 2026, allowing key employees to defer significant portions of salary and bonuses. Additionally, Dr. Rebecca Taub will transition from an employee to a consultant effective July 1, 2026, providing scientific guidance for MASH programs for $100,000 annually while maintaining her board seat. The company also re-elected three Class I directors and ratified PricewaterhouseCoopers LLP as its independent auditor. Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing treatments for liver diseases.